📰 A 1726 News
A 1726 News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from A 1726. Real-time updates on events, politics, business and more.
February 1, 2024
NeuroBo Pharmaceuticals, Inc. (NRBO) announced on Thursday that the FDA has approved its Investigational New Drug or IND application for DA-1726, a new dual oxyntomodulin analog agonist.
February 1, 2024
Stock of NeuroBo Pharmaceuticals, Inc. (NRBO) gained 48 percent on Thursday after the FDA approved the company's Investigational New Drug or IND application for DA-1726, a new dual oxyntomodulin analog agonist.
December 28, 2023
NeuroBo Pharmaceuticals, Inc. (NRBO), a clinical-stage biotechnology company, Thursday said it has submitted Investigational New Drug or IND application to FDA, regarding Phase 1 clinical trial of DA-1726 for the treatment of obesity.